Things are looking up –

Mar. 16, 2019 – Hence the interest in a recent announcement by the Food and Drug Administration (FDA) in America that it had approved a new drug for patients with “treatment-resistant” depression, defined as having not responded adequately to at least two previous antidepressants. Of particular note is that it is based on ketamine, a recreational drug. Esketamine, as the chemical is known, is branded as Spravato by its developer, Janssen Pharmaceuticals, a branch of Johnson & Johnson.

Full Story @ Economist.com

SIGN UP TODAY!

Subscribe Today! Your best source of current news, information and opinion about the issues that matter to you most. Serving the treatment industry, recovery community and health and wellness professionals.